Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review
Open Access
- 3 September 2024
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (12) , 2522-2532
Abstract
There is increasing evidence that cannabidiol (CBD) use is associated with clinically significant liver enzyme (LE) elevations and drug‐induced liver injury (DILI). The proportion of LE elevations and DILI events reported in the literature meet the Council for International Organizations of Medical Sciences' (CIOMS) classification of a common adverse drug reaction. However, these potential adverse events are unknown to many clinicians and may be overlooked. The increasing use of CBD for both medical and non‐medical use necessitates clear direction in the diagnosis and management of CBD‐associated hepatotoxicity. To our knowledge, no such clinical guidance currently exists. For people presenting with elevated LEs, CBD use should be screened for and be considered in the differential diagnosis. This narrative review will provide clinicians with guidance in the prevention, detection, and management of CBD‐related hepatotoxicity.Keywords
This publication has 74 references indexed in Scilit:
- Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US AdultsJAMA Network Open, 2023
- Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant EpilepsyClinical Pharmacology & Therapeutics, 2021
- Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 PandemicJAMA Network Open, 2021
- A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy SubjectsClinical Pharmacology in Drug Development, 2021
- Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis ComplexJAMA Neurology, 2021
- Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical TrialClinical Pharmacology & Therapeutics, 2020
- A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy SubjectsClinical Pharmacology in Drug Development, 2019
- Labeling Accuracy of Cannabidiol Extracts Sold OnlineJAMA, 2017
- Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis ProductsJAMA, 2015
- Standardization of nomenclature and causality assessment in drug‐induced liver injuryHepatology, 2010